Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)

Exclusion Criteria

• •1. History of bleeding diathesis or coagulopathy
• •2. Pregnant state
• •3. Known hypersensitivity or contra-indication to contrast agent and heparin
• •4. Limited life-expectancy (less than 1 year)
• •5. ST-elevation acute myocardial infraction requiring primary stenting
• •6. Characteristics of lesion: left main disease, in-stent restenosis, graft vessels
• •7. Hematological disease (Neutropenia \< 3000/mm3), Thrombocytopenia \< 100,000/mm3)
• •8. Hepatic dysfunction, liver enzyme (ALT and AST) elevation ≥ 3times normal
• •9. Renal dysfunction, creatinine ≥ 2.0mg/dL
• •10. Contraindication to aspirin, clopidogrel or cilostazol
• •11. Contraindication to Paclitaxel or everolimus
• •12. Left ventricular ejection fraction \< 30%
• •13. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period
• •14. Non-cardiac co-morbid conditions are present with life expectancy \< 1 year or that may result in protocol non-compliance (per site investigator's medical judgment for example: oxygen dependent chronic obstructive pulmonary disease, active hepatitis or severe liver function or kidney disease)